Dietary Supplements, Inflammation, Long Covid19, Respiratory Tract Infections
Conditions
Keywords
COVID-19, dietary supplementation, inflammation, lung function, muscle strength, SARS-CoV-2
Brief summary
Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients. Objectives: Thus, the present study investigated whether 30 days of supplementation with a nutritional blend (ImmuneRecov®; composition: whey protein concentrate, astaxanthin, creatine, selenium, vitamin C, glutamic acid, tryptophan, magnesium) would help to minimize the respiratory (lung function) and muscular (respiratory and peripheral muscles) sequelae in post-COVID-19 patients.
Detailed description
Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients. Objectives: Thus, the present study investigated whether 30 days of supplementation with a nutritional blend (ImmuneRecov®; composition: whey protein concentrate, astaxanthin, creatine, selenium, vitamin C, glutamic acid, tryptophan, magnesium) would help to minimize the respiratory (lung function) and muscular (respiratory and peripheral muscles) sequelae in post-COVID-19 patients. Design: This is a non-controlled open label prospective clinical study. Methods: Fifty-eight post-COVID-19 patients were recruited and twenty-four accepted to take the nutritional blend, while twenty-four did not accept but required to participate in the evaluations and 10 refused to participate. So, the patients were evaluated before the 14th day after hospital discharge and after 30 days of use of the nutritional blend or control (no supplementation).
Interventions
DIETARY_SUPPLEMENTNutritional blend (ImmuneRecov).
Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
Sponsors
Federal University of São Paulo
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The inclusion criteria encompassed post-COVID-19 patients with a confirmed COVID-19 diagnosis through a positive RT-PCR test, who also required hospitalization, meeting the criteria for moderate severity classification as defined by the World Health Organization (WHO). In summary, according to the WHO, moderate illness is characterized by individuals who exhibit signs of lower respiratory disease during clinical assessment or imaging and maintain an oxygen saturation level (SpO2) of ≥94% while breathing room air at sea level.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effects of ImmuneRecov on Lung Function and Immune Response | Effects of 30 days supplementation with ImmuneRecov on Lung Function and Immune Response | Effects of ImmuneRecov on Lung Function and Immune Response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effects of ImmuneRecov on Peripheral and Respiratory Muscle Strength | Effects of 30 days of ImmuneRecov supplementation on Peripheral and Respiratory Muscle Strength | Effects of 30 days of ImmuneRecov supplementation on Peripheral and Respiratory Muscle Strength |
Countries
Brazil
Contacts
Primary ContactRodolfo de Paula Vieira, BSc., MSc., PhD.
Outcome results
None listed